Sermorelin

What it is

Sermorelin is the first 29 residues of human growth-hormone-releasing hormone — GRF(1-29), sometimes written GHRH(1-29). Native GHRH is 44 residues, and the truncation is not arbitrary: the N-terminal 29 residues retain essentially the full receptor-activating capability of the parent hormone, which made the fragment the natural minimal construct for studying GHRH receptor biology.

It binds the GHRH receptor, a class B G-protein-coupled receptor on somatotroph cells of the anterior pituitary. Activation raises intracellular cAMP and promotes synthesis and release of stored growth hormone.

Why the GHRH axis is studied through a fragment

The pituitary sits under two opposing controls: GHRH pushes growth-hormone release, somatostatin restrains it, and the interaction of the two produces the pulsatile secretion pattern seen in vivo. A short, well-defined GHRH-receptor agonist is a cleaner experimental tool for probing that system than the full 44-residue hormone.

Sermorelin is short-acting — it is cleaved rapidly by DPP-4 at the N-terminus, like GHRH itself. In a research context that is often a feature rather than a limitation: a brief, defined stimulus is what you want when the question is about pulse dynamics or receptor desensitisation rather than sustained elevation.

This is also the distinction that separates it from analogs such as tesamorelin and CJC-1295, which carry modifications specifically intended to resist that cleavage and extend duration. Comparing a short-acting fragment against a stabilised analog is a standard way of isolating what duration of receptor occupancy actually changes downstream.

Secretagogue class distinctions

Growth-hormone secretagogues divide into two mechanistic families that are frequently conflated. GHRH-receptor agonists — sermorelin, tesamorelin, CJC-1295 — act on the GHRH receptor. Ghrelin-receptor agonists — ipamorelin, GHRP-6, hexarelin — act on the growth-hormone secretagogue receptor GHS-R1a, a different receptor with a different signalling cascade.

Because the two families converge on the same output through different receptors, they are often studied in combination in preclinical models, and the interaction is a research subject in its own right. Reading the literature accurately depends on keeping the receptor straight — a compound described loosely as a 'GH peptide' could belong to either family.

Pulsatility, and why a short-acting agonist suits it

Growth hormone is not secreted at a steady rate. It comes in discrete bursts, largely during slow-wave sleep, and the pattern of those bursts — amplitude, frequency, and the troughs between them — carries information that a time-averaged concentration destroys.

Downstream tissues respond to the pattern, not only the total. An experimental design producing sustained elevation therefore answers a different question from one producing a defined pulse, which makes the pharmacokinetics of the tool compound part of the design rather than an incidental property of it.

A short-acting GHRH-receptor agonist gives a pulse; a stabilised analog gives sustained occupancy. Running both in the same model is a direct way to ask what the pattern itself contributes.

Where the cleavage site sits

Dipeptidyl peptidase-4 removes dipeptides from the N-terminus of susceptible peptides, and the N-terminal region of GHRH is exactly where its receptor-activating residues sit. The part that must stay intact for activity is the part the enzyme takes first.

Every long-acting analog in this family is an answer to that single constraint. Tesamorelin carries an N-terminal modification; CJC-1295 substitutes residues at the cleavage site and, in its DAC form, adds albumin binding on top. Read as a series of responses to one problem, the structural differences stop looking arbitrary.

Not stocked here

We do not sell sermorelin. We do stock other compounds in the growth-hormone axis, and this entry is here because the GHRH-versus-ghrelin-receptor distinction is the single most useful thing to understand before reading about any of them.

For laboratory research use only. Preclinical reference information; not guidance for use.